Anlon Healthcare IPO Draws Big Retail Buzz, Oversubscribed 7x Ahead of Listing
Retail Investors Lead the Surge as Pharma IPO Closes Heavily Subscribed
The ₹121-crore initial public offering of Anlon Healthcare Ltd closed with resounding investor interest this week, posting a 7.13x overall subscription as demand soared across categories, particularly among retail participants.
The public issue, which ran from August 26 to 29, struck a chord with individual investors, with the retail quota subscribed nearly 47 times, far outpacing other segments. Non-institutional investors subscribed 10.63 times, while qualified institutional buyers remained relatively subdued at 1.07 times.
Anlon, a pharmaceutical company focused on high-purity APIs and intermediates, is one of the few Indian manufacturers of loxoprofen sodium dihydrate, an anti-inflammatory active ingredient approved for export in key regulated markets, including Japan, Brazil, and China.
Backed by a solid track record, the company has reported an 81% jump in revenue and a 112% surge in net profit over the last two financial years. The performance, coupled with the company’s role in India’s growing pharmaceutical manufacturing ecosystem, appears to have drawn investor confidence despite a cautious broader market tone.
The company’s IPO is priced at ₹91 per share. As of the final bidding day, the stock was commanding a grey market premium of ₹2–₹5, suggesting a muted but positive listing sentiment, with estimated listing gains of up to 5.5%.
While the GMP remains modest, the strength of retail participation has positioned Anlon’s upcoming debut on investor watchlists. The basis of allotment is expected to be finalised on September 1, with listing slated for September 3 on both NSE and BSE.
Shares will be credited to successful applicants by September 2. The registrar for the issue is KFin Technologies.